Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial.

Pan-Pan ZhangYiyi GongZheng LiuYanying LiuWei LinJieqiong LiMu WangXiaowei LiuYunyun FeiHua ChenLinyi PengJing LiJiaxin ZhouQun ShiXuan ZhangMin ShenXiaofeng ZengFengchun ZhangYongzhe LiYan ZhaoWen Zhang

Published in: International journal of rheumatic diseases (2019)

Iguratimod plus corticosteroid as bridge therapy is effective for the treatment of mild IgG4-RD, it can improve the clinical symptoms, reduce serum IgG and IgG4 levels, especially plasmablasts/plasma cells and memory B cells. In addition, the metabolite profiling became similar to normal controls after treatment.

Keyphrases

clinical trial
induced apoptosis
cell cycle arrest
single cell
stem cells
open label
oxidative stress
depressive symptoms
cell proliferation
cell death
study protocol
phase ii
endoplasmic reticulum stress
cell therapy
phase iii
pi k akt